Jackie Walling

2.5k total citations · 1 hit paper
45 papers, 1.9k citations indexed

About

Jackie Walling is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Jackie Walling has authored 45 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Molecular Biology, 12 papers in Pulmonary and Respiratory Medicine and 12 papers in Oncology. Recurrent topics in Jackie Walling's work include Amyloidosis: Diagnosis, Treatment, Outcomes (11 papers), Multiple Myeloma Research and Treatments (8 papers) and Cancer Treatment and Pharmacology (7 papers). Jackie Walling is often cited by papers focused on Amyloidosis: Diagnosis, Treatment, Outcomes (11 papers), Multiple Myeloma Research and Treatments (8 papers) and Cancer Treatment and Pharmacology (7 papers). Jackie Walling collaborates with scholars based in United States, United Kingdom and Italy. Jackie Walling's co-authors include J Carmichael, H H Hansen, Heather Anderson, Birthe Lund, N. Thatcher, Flemming W. Bach, Adrian L. Harris, Helen Kerr, K. Possinger and Maria K. Beykirch and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Jackie Walling

43 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer

2020 259 citations Jackie Walling et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jackie Walling United States	16	1.0k	878	671	252	154	45	1.9k
Frauke Bentzien United States	10	665 0.7×	522 0.6×	821 1.2×	298 1.2×	92 0.6×	12	2.1k
L. Austin Doyle United States	27	881 0.9×	850 1.0×	1.1k 1.6×	398 1.6×	214 1.4×	71	2.2k
Kristi A. Boehm United States	24	1.5k 1.4×	736 0.8×	495 0.7×	720 2.9×	159 1.0×	77	2.3k
Mayu Yunokawa Japan	25	1.1k 1.1×	482 0.5×	511 0.8×	373 1.5×	82 0.5×	140	2.1k
Amna Ibrahim United States	26	1.7k 1.7×	1.1k 1.2×	744 1.1×	457 1.8×	207 1.3×	58	2.9k
Panos Fidias United States	25	1.7k 1.7×	1.8k 2.1×	925 1.4×	276 1.1×	116 0.8×	58	3.0k
G. Deplanque France	23	1.3k 1.3×	812 0.9×	633 0.9×	542 2.2×	65 0.4×	77	2.3k
Paul Hamberg Netherlands	26	927 0.9×	1.0k 1.2×	633 0.9×	624 2.5×	66 0.4×	118	2.1k
Reinhard von Roemeling United States	23	728 0.7×	626 0.7×	774 1.2×	606 2.4×	90 0.6×	72	2.0k
Elena De Mattia Italy	25	963 0.9×	324 0.4×	725 1.1×	279 1.1×	95 0.6×	92	2.0k

Countries citing papers authored by Jackie Walling

Since Specialization

Citations

This map shows the geographic impact of Jackie Walling's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jackie Walling with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jackie Walling more than expected).

Fields of papers citing papers by Jackie Walling

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jackie Walling. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jackie Walling. The network helps show where Jackie Walling may publish in the future.

Co-authorship network of co-authors of Jackie Walling

This figure shows the co-authorship network connecting the top 25 collaborators of Jackie Walling. A scholar is included among the top collaborators of Jackie Walling based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jackie Walling. Jackie Walling is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Matusow, Bernice, Sadegh Saghafinia, Panyu Chen, et al.. (2024). OPN-6602, an Orally Bioavailable EP300/CBP Bromodomain Inhibitor, Targets Multiple Myeloma through Suppression of IRF4 and MYC. Blood. 144(Supplement 1). 1908–1908. 1 indexed citations

Matusow, Bernice, Wayne Spevak, Yan Ma, et al.. (2024). Abstract 660: OPN-6602, a potent dual EP300/CBP bromodomain inhibitor, targets multiple myeloma through concomitant suppression of IRF4 and c-MYC. Cancer Research. 84(6_Supplement). 660–660.

Swisher, Elizabeth M., Linda Duska, Erika Hamilton, et al.. (2023). Abstract CT160: Phase 1b/2a clinical trial of the oral BET inhibitor PLX2853 as monotherapy for ARID1A mutated gynecologic cancers and in combination with carboplatin for platinum resistant ovarian cance. Cancer Research. 83(8_Supplement). CT160–CT160. 3 indexed citations

Gertz, Morie A., Raymond L. Comenzo, Heather Landau, et al.. (2017). Organ Biomarker Responses in Patients With Light Chain Amyloidosis Treated With NEOD001 Are Independent of Previous Hematologic Response. Clinical Lymphoma Myeloma & Leukemia. 17(1). e97–e98. 2 indexed citations

Gertz, Morie A., Heather Landau, Raymond L. Comenzo, et al.. (2016). First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction. Journal of Clinical Oncology. 34(10). 1097–1103. 147 indexed citations

Liedtke, Michaela, Raymond L. Comenzo, Heather Landau, et al.. (2016). NEOD001 DEMONSTRATES CARDIAC AND RENAL BIOMARKER RESPONSES IN A PHASE 1/2 STUDY IN PATIENTS WITH AMYLOID LIGHT CHAIN AMYLOIDOSIS AND PERSISTENT ORGAN DYSFUNCTION. Journal of the American College of Cardiology. 67(13). 1301–1301. 1 indexed citations

Liedtke, Michaela, Giampaolo Merlini, Heather Landau, et al.. (2016). The VITAL Amyloidosis Study: A Randomized, Double-Blind, Placebo-Controlled, Global, Phase 3 Study of NEOD001 in Patients with AL Amyloidosis and Cardiac Dysfunction. Blood. 128(22). 5690–5690. 6 indexed citations

Gertz, Morie A., Raymond L. Comenzo, Heather Landau, et al.. (2016). NEOD001 Demonstrates Organ Biomarker Responses in Patients with Light Chain Amyloidosis and Persistent Organ Dysfunction: Results from the Expansion Cohort of a Phase 1/2 Study. Blood. 128(22). 644–644. 9 indexed citations

Swords, Ronan, Peter L. Greenberg, Andrew H. Wei, et al.. (2016). KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study. Leukemia Research. 50. 123–131. 46 indexed citations

10.

Lancet, Jeffrey E., Andrew H. Wei, S. T. S. Durrant, et al.. (2013). A Phase I Study Of KB004, a Novel Non-Fucosylated humaneered® Antibody, Targeted Against The Receptor Tyrosine Kinase EphA3, In Advanced Hematologic Malignancies. Blood. 122(21). 3838–3838. 5 indexed citations

11.

Walling, Jackie. (2005). From methotrexate to pemetrexed and beyond. A review of the pharmacodynamic and clinical properties of antifolates. Investigational New Drugs. 24(1). 37–77. 134 indexed citations

12.

Budman, Daniel R., Robert D. Johnson, Ronald R. Bowsher, et al.. (2001). Phase I and pharmacokinetic study of LY309887: a specific inhibitor of purine biosynthesis. Cancer Chemotherapy and Pharmacology. 47(6). 525–531. 19 indexed citations

13.

Carmichael, J & Jackie Walling. (1997). Advanced breast cancer: Investigational role of gemcitabine. European Journal of Cancer. 33. S27–S30. 24 indexed citations

14.

Anderson, Helén, Nicholas Thatcher, Jackie Walling, & H H Hansen. (1996). A phase I study of a 24 hour infusion of gemcitabine in previously untreated patients with inoperable non-small-cell lung cancer. British Journal of Cancer. 74(3). 460–462. 52 indexed citations

15.

Carmichael, J, K. Possinger, Maria K. Beykirch, et al.. (1995). Advanced breast cancer: a phase II trial with gemcitabine.. Journal of Clinical Oncology. 13(11). 2731–2736. 302 indexed citations

16.

Anderson, Heather, Birthe Lund, Flemming W. Bach, et al.. (1994). Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study.. Journal of Clinical Oncology. 12(9). 1821–1826. 310 indexed citations

17.

Talbot, Denis, et al.. (1993). Phase II trial of the novel sulphonylurea sulofenur in advanced breast cancer. Cancer Chemotherapy and Pharmacology. 31(5). 419–422. 19 indexed citations

18.

Scarffe, J H, et al.. (1992). A phase II study of sulofenur (LY186641) in gastric cancer. Anti-Cancer Drugs. 3(4). 331–336. 15 indexed citations

19.

O’Brien, Mary, et al.. (1992). A phase II study of sulofenur, a novel sulfonylurea, in recurrent epithelial ovarian cancer. Cancer Chemotherapy and Pharmacology. 30(3). 245–248. 15 indexed citations

20.

Walling, Jackie, et al.. (1991). Role of the extracellular matrix on the growth and differentiated phenotype of murine colonic adenocarcinoma cells in vitro. International Journal of Cancer. 47(5). 776–783. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact